Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype

Neuropharmacology

Volumn 70, Issue , 2013, Pages 211-217

  Cates, Lindsay N ^a   Roberts, Amanda J ^a   Huitron Resendiz, Salvador ^a   Hedlund, Peter B ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Forced swim test; Knockout; Mood; Repeated open space swim test; Serotonin; Tail suspension test

Indexed keywords

CITALOPRAM; LURASIDONE; SEROTONIN 7 RECEPTOR;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; EXPERIMENTAL TEST; FORCED SWIMMING TEST; IMMOBILIZATION; LIGHT DARK CYCLE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL SUSPENSION TEST;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSION; ISOINDOLES; MALE; MICE; MICE, KNOCKOUT; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; THIAZOLES;

EID: 84877004426     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.01.023     Document Type: Article

References (66)

1. A. Abbas, P.B. Hedlund, X.P. Huang, T.B. Tran, H.Y. Meltzer, and B.L. Roth Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo Psychopharmacology (Berl.) 205 2009 119 128
2. P.R. Albert, B. Le François, and A.M. Millar Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness Mol. Brain 4 2011 21
3. F. Artigas Serotonin receptors involved in antidepressant effects Pharmacol. Ther. 137 2013 119 131
4. J.A. Bard, J. Zgombick, N. Adham, P. Vaysse, T.A. Branchek, and R.L. Weinshank Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase J. Biol. Chem. 268 1993 23422 23426
5. L. Bartova, A. Berger, and L. Pezawas Is there a personalized medicine for mood disorders? Eur. Arch. Psychiatry Clin. Neurosci. 260 Suppl 2 2010 S121 S126
6. M.A. Belenky, and G.E. Pickard Subcellular distribution of 5-HT1B and 5-HT7 receptors in the mouse suprachiasmatic nucleus J. Comp. Neurol. 432 2001 371 388
7. R.M. Berman, M. Fava, M.E. Thase, M.H. Trivedi, R. Swanink, R.D. McQuade, W.H. Carson, D. Adson, L. Taylor, J. Hazel, and R.N. Marcus Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants CNS Spectr. 14 2009 197 206
8. L. Berrade, B. Aisa, M.J. Ramirez, S. Galiano, S. Guccione, L.R. Moltzau, F.O. Levy, F. Nicoletti, G. Battaglia, G. Molinaro, I. Aldana, A. Monge, and S. Perez-Silanes Novel benzo[b]thiophene derivatives as new potential antidepressants with rapid onset of action J. Med. Chem. 54 2011 3086 3090
9. P. Blier The well of novel antidepressants: running dry J. Psychiatry Neurosci. 35 2010 219 220
10. P. Bonaventure, C. Dugovic, M. Kramer, P. De Boer, J. Singh, S. Wilson, K. Bertelsen, J. Di, J. Shelton, L. Aluisio, L. Dvorak, I. Fraser, B. Lord, D. Nepomuceno, A. Ahnaou, W. Drinkenburg, W. Chai, C. Dvorak, N. Carruthers, S. Sands, and T. Lovenberg Translational evaluation of JNJ-18038683, a 5-HT7 receptor antagonist, on REM sleep and in major depressive disorder J. Pharmacol. Exp. Ther. 342 2012 429 440
11. P. Bonaventure, L. Kelly, L. Aluisio, J. Shelton, B. Lord, R. Galici, K. Miller, J. Atack, T.W. Lovenberg, and C. Dugovic Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents J. Pharmacol. Exp. Ther. 321 2007 690 698
12. F.J. Bosker, J.H.A. Folgering, A.V. Gladkevich, A. Schmidt, M.C.G. Hart van der, J. Sprouse, J.A. Boer den, B.H.C. Westerink, and T.I.F.H. Cremers Antagonism of 5-HT1A receptors uncovers an excitatory effect of SSRIs on 5-HT neuronal activity, an action probably mediated by 5-HT7 receptors J. Neurochem. 108 2009 1126 1135
13. L. Citrome Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics Postgrad. Med. 123 2011 153 162
14. L. Citrome, J. Cucchiaro, K. Sarma, D. Phillips, R. Silva, S. Tsuchiya, and A. Loebel Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study Int. Clin. Psychopharmacol. 27 2012 165 176
15. B.G. Druss, I. Hwang, M. Petukhova, N.A. Sampson, P.S. Wang, and R.C. Kessler Impairment in role functioning in mental and chronic medical disorders in the United States: results from the National Comorbidity Survey Replication Mol. Psychiatry 14 2009 728 737
16. N. Elizalde, F.J. Gil-Bea, M.J. Ramírez, B. Aisa, B. Lasheras, J. Del Rio, and R.M. Tordera Long-lasting behavioral effects and recognition memory deficit induced by chronic mild stress in mice: effect of antidepressant treatment Psychopharmacology (Berl.) 199 2008 1 14
17. T. Enomoto, T. Ishibashi, K. Tokuda, T. Ishiyama, S. Toma, and A. Ito Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats Behav. Brain Res. 186 2008 197 207
18. F. Ferrari, and D. Giuliani Effects of (-)eticlopride and 7-OH-DPAT on the tail-suspension test in mice J. Psychopharmacol. 11 1997 339 344
19. F. Fumagalli, F. Calabrese, A. Luoni, F. Bolis, G. Racagni, and M.A. Riva Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress Int. J. Neuropsychopharmacol. 15 2012 235 246
20. P.E. Greenberg, R.C. Kessler, H.G. Birnbaum, S.A. Leong, S.W. Lowe, P.A. Berglund, and P.K. Corey-Lisle The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry 64 2003 1465 1475
21. M. Guscott, L.J. Bristow, K. Hadingham, T.W. Rosahl, M.S. Beer, J.A. Stanton, F. Bromidge, A.P. Owens, I. Huscroft, J. Myers, N.M. Rupniak, S. Patel, P.J. Whiting, P.H. Hutson, K.C. Fone, S.M. Biello, J.J. Kulagowski, and G. McAllister Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression Neuropharmacology 48 2005 492 502
22. L.G. Harsing, I. Prauda, J. Barkoczy, P. Matyus, and Z. Juranyi A 5-HT7 heteroreceptor-mediated inhibition of [3H]serotonin release in raphe nuclei slices of the rat: evidence for a serotonergic-glutamatergic interaction Neurochem. Res. 29 2004 1487 1497
23. P.D. Harvey, M. Ogasa, J. Cucchiaro, A. Loebel, and R.S.E. Keefe Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone Schizophr. Res. 127 2011 188 194
24. P.B. Hedlund The 5-HT7 receptor and disorders of the nervous system: an overview Psychopharmacology (Berl.) 206 2009 345 354
25. P.B. Hedlund, P.E. Danielson, E.A. Thomas, K. Slanina, M.J. Carson, and J.G. Sutcliffe No hypothermic response to serotonin in 5-HT7 receptor knockout mice Proc. Natl. Acad. Sci. USA 100 2003 1375 1380
26. P.B. Hedlund, S. Huitron-Resendiz, S.J. Henriksen, and J.G. Sutcliffe 5-HT7 receptor inhibition and inactivation induce antidepressant like behavior and sleep pattern Biol. Psychiatry 58 2005 831 837
27. M. Horiguchi, M. Huang, and H.Y. Meltzer The role of 5-HT7 receptors in the phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats J. Pharmacol. Exp. Ther. 338 2011 605 614
28. T. Ishibashi, T. Horisawa, K. Tokuda, T. Ishiyama, M. Ogasa, R. Tagashira, K. Matsumoto, H. Nishikawa, Y. Ueda, S. Toma, H. Oki, N. Tanno, I. Saji, A. Ito, Y. Ohno, and M. Nakamura Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-HT7 and 5-HT1A receptor activity J. Pharmacol. Exp. Ther. 334 2010 171 181
29. T. Ishiyama, K. Tokuda, T. Ishibashi, A. Ito, S. Toma, and Y. Ohno Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test Eur. J. Pharmacol. 572 2007 160 170
30. J. Kamei, S. Miyata, T. Sunohara, A. Kamei, M. Shimada, and M. Ohsawa Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in the mouse tail suspension test J. Pharmacol. Sci. 108 2008 381 384
31. M.A. Katzman Current considerations in the treatment of generalized anxiety disorder CNS Drugs 23 2009 103 120
32. S.H. Kennedy, and S.J. Rizvi Emerging drugs for major depressive disorder Expert Opin. Emerg. Drugs 14 2009 439 453
33. R.C. Kessler, P. Berglund, O. Demler, R. Jin, K.R. Merikangas, and E.E. Walters Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication Arch. Gen. Psychiatry 62 2005 593 602
34. W.K. Kroeze, S.J. Hufeisen, B.A. Popadak, S.M. Renock, S. Steinberg, P. Ernsberger, K. Jayathilake, H.Y. Meltzer, and B.L. Roth H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs Neuropsychopharmacology 28 2003 519 526
35. Y. Lecrubier, P. Boyer, S. Turjanski, and W. Rein Amisulpride versus imipramine and placebo in dysthymia and major depression J. Affect. Disord. 43 1997 95 103
36. T.W. Lovenberg, B.M. Baron, L. De Lecea, J.D. Miller, R.A. Prosser, M.A. Rea, P.E. Foye, M. Racke, A.L. Slone, B.W. Siegel, P.E. Danielson, J.G. Sutcliffe, and M.G. Erlander A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms Neuron 11 1993 449 458
37. J.G. McEuen, K.A. Semsar, M.A. Lim, and T.L. Bale Influence of sex and corticotropin-releasing factor pathways as determinants in serotonin sensitivity Endocrinology 150 2009 3709 3716
38. H.Y. Meltzer, J. Cucchiaro, R. Silva, M. Ogasa, D. Phillips, J. Xu, A.H. Kalali, E. Schweizer, A. Pikalov, and A. Loebel Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study Am. J. Psychiatry 168 2011 957 967
39. J.M. Meyer, A.D. Loebel, and E. Schweizer Lurasidone: a new drug in development for schizophrenia Expert Opin. Investig. Drugs 18 2009 1715 1726
40. M.J. Millan Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs Neurotherapeutics 6 2009 53 77
41. M.J. Millan, A. Dekeyne, M. Papp, C.D.L. Rochelle, C. MacSweeny, J.-L. Peglion, and M. Brocco S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine J. Pharmacol. Exp. Ther. 298 2001 581 591
42. O. Mnie-Filali, C. Faure, L. Lambás-Señas, M.E. Mansari, H. Belblidia, E. Gondard, A. Etiévant, H. Scarna, A. Didier, A. Berod, P. Blier, and N. Haddjeri Pharmacological blockade of 5-HT(7) receptors as a putative fast acting antidepressant strategy Neuropsychopharmacology 36 2011 1275 1288
43. O. Mnie-Filali, L. Lambas-Señas, H. Scarna, and N. Haddjeri Therapeutic potential of 5-HT(7) receptors in mood disorders Curr. Drug Targets 10 2009 1109 1117
44. C. Mombereau, T.L. Gur, J. Onksen, and J.A. Blendy Differential effects of acute and repeated citalopram in mouse models of anxiety and depression Int. J. Neuropsychopharmacol. 13 2010 321 334
45. M. Nakamura, M. Ogasa, J. Guarino, D. Phillips, J. Severs, J. Cucchiaro, and A. Loebel Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial J. Clin. Psychiatry 70 2009 829 836
46. L.S. Nandam, D. Jhaveri, and P. Bartlett 5-HT7, neurogenesis and antidepressants: a promising therapeutic axis for treating depression Clin. Exp. Pharmacol. Physiol. 34 2007 546 551
47. J.C. Nelson, A. Pikalov, and R.M. Berman Augmentation treatment in major depressive disorder: focus on aripiprazole Neuropsychiatr. Dis. Treat. 4 2008 937 948
48. E.J. Nestler, and S.E. Hyman Animal models of neuropsychiatric disorders Nat. Neurosci. 13 2010 1161 1169
49. M. Papp, and J. Wieronska Antidepressant-like activity of amisulpride in two animal models of depression J. Psychopharmacol. 14 2000 46 52
50. R.D. Porsolt, A. Bertin, and M. Jalfre Behavioral despair in mice: a primary screening test for antidepressants Arch. Int. Pharmacodyn. Ther. 229 1977 327 336
51. J.W. Richardson-Jones, C.P. Craige, B.P. Guiard, A. Stephen, K.L. Metzger, H.F. Kung, A.M. Gardier, A. Dranovsky, D.J. David, S.G. Beck, R. Hen, and E.D. Leonardo 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants Neuron 65 2010 40 52
52. M. Ruat, E. Traiffort, R. Leurs, J. Tardivel-Lacombe, J. Diaz, J.M. Arrang, and J.C. Schwartz Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation Proc. Natl. Acad. Sci. USA 90 1993 8547 8551
53. C. Sanchez, P.B. Bergqvist, L. Brennum, S. Gupta, S. Hogg, A. Larsen, and O. Wiborg Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities Psychopharmacology (Berl.) 167 2003 353 362
54. G. Sarkisyan, A.J. Roberts, and P.B. Hedlund The 5-HT7 receptor as a mediator and modulator of antidepressant-like behavior Behav. Brain Res. 209 2010 99 108
55. D.A. Shapiro, S. Renock, E. Arrington, L.A. Chiodo, L.-X. Liu, D.R. Sibley, B.L. Roth, and R. Mailman Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology Neuropsychopharmacology 28 2003 1400 1411
56. Y. Shen, F.J. Monsma, M.A. Metcalf, P.A. Jose, M.W. Hamblin, and D.R. Sibley Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype J. Biol. Chem. 268 1993 18200 18204
57. E. Smeraldi Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study J. Affect. Disord. 48 1998 47 56
58. L. Steru, R. Chermat, B. Thierry, and P. Simon The tail suspension test: a new method for screening antidepressants in mice Psychopharmacology (Berl.) 85 1985 367 370
59. P.E. Stokes, and A. Holtz Fluoxetine tenth anniversary update: the progress continues Clin. Ther. 19 1997 1135 1250
60. E.A. Stone, M.L. Lehmann, Y. Lin, and D. Quartermain Reduced evoked fos expression in activity-related brain regions in animal models of behavioral depression Prog. Neuropsychopharmacol. Biol. Psychiatry 31 2007 1196 1207
61. E.A. Stone, and Y. Lin Open-space forced swim model of depression for mice Curr. Protoc. Neurosci. 2011 (Chapter 9, Unit 9.36)
62. E.A. Stone, Y. Lin, and D. Quartermain Evaluation of the repeated open-space swim model of depression in the mouse Pharmacol. Biochem. Behav. 91 2008 190 195
63. A. Wesolowska, and M. Kowalska Influence of serotonin 5-HT7 receptor blockade on the behavioral and neurochemical effects of imipramine in rats Pharmacol. Rep. 60 2008 464 474
64. A. Wesolowska, A. Nikiforuk, and K. Stachowicz Potential anxiolytic and antidepressant effects of the selective 5-HT7 receptor antagonist SB 269970 after intrahippocampal administration to rats Eur. J. Pharmacol. 553 2006 185 190
65. A. Wesolowska, A. Nikiforuk, K. Stachowicz, and E. Tatarczynska Effect of the selective 5-HT(7) receptor antagonist SB 269970 in animal models of anxiety and depression Neuropharmacology 51 2006 578 586
66. A. Wesolowska, E. Tatarczynska, A. Nikiforuk, and E. Chojnacka-Wojcik Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice Eur. J. Pharmacol. 555 2007 43 47